logoalt Hacker News

MBCooklast Thursday at 5:00 AM1 replyview on HN

That was one of my first thoughts.

It’s perfectly possible for a new hot to have a severe side effect that won’t be noticed for quite a long time.

Semiglutide appears to have undergone final clinical trials in the US around 2017. Given it hasn’t been on the market terribly long and has only an exploded in popularity relatively recently it doesn’t seem like it would be that hard for it to have a serious side effect in a small portion of the population that hadn’t been detected before due to the limited number of people taking it, the amount of time it takes to manifest, or both.

Obviously it’s providing significant benefit that risk could easily be worth it. But as it gets marketed towards more and more people that won’t be true for all of them.


Replies

cthalupalast Thursday at 5:19 AM

Semaglutide is a 3rd generation GLP-1 agonist, though. We're 20 years in on GLP-1s at this point.